life scienc tool diagnost
beat estim better revenu profit factor
line ad lift revenu profit outlook
call revenu vs consensu ebitda
million midpoint vs con million like reflect hire
dynam element conservat rais ep
reflect beat dynam low line
price move higher view
revenu profit prevail strong net btb vs estimate
total revenu jump well ahead plan post
impress net book-to-bil nice backlog
convers vs estimate improv bp sequenti
billion note
conserv book polici support above-industri backlog burn
strength ebitda margin contract bp bp ahead
plan continu step invest support growth flow
million help pay remain debt cash reserv
stand million net dso rose day
emphas
momentum continu medp share larg recov
recent low march vs view momentum
share continu latest book strength note
favor underli demand cancel subsid elev
level past two quarter updat guidanc continu
impli step-down ebitda margin await call commentari
hire headcount profit dynam balanc year
along detail industri fundament particularli across smid biotech
custom revenue risk project cancel biotech fund
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
medpac full-servic therapeutically-focus contract
servic biopharmaceut medic devic industri
price jul rate outperform target price analyst erin wright
profit tax
chang work capit
oper
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat assum signific
acceler organ sale growth healthi fund environ
increas profit success new servic offer
substanti new busi win continu strong outsourc
demand small/mid-s biotech custom
grey sky valuat assum deceler
sale growth declin profit weaken demand
small/mid-s biotech custom custom consolid
slowdown overal spend
 close
result exceed cs consensu expect driven stronger revenu
profit book exceed expect quarterli net book-to-bil
top expect acceler rel btb previou
quarter net new busi step million yoy backlog
convers improv sequenti basi vs focu
tuesday confer call like profit dynam second half natur
recent new busi win well underli health industri fundament
particularli across core custom base smid biopharma repres
context one conserv book polici across public
cro univers includ maximum three year expect revenu
given project backlog recogn project backlog begun
gener revenu key contribut factor industry-lead backlog convers
rate lower book-to-bil rel peer thu emphas import
look two metric backlog convers book-to-bil simultan
book-to-bil compar due
note industri averag adjust vari definit recognit backlog less aggress depend compani
guidanc detail provid revis top-line guidanc rais revenu
expect million midpoint vs prior reflect
strengthen new busi momentum stronger anticip backlog convers
trend await greater detail cancellation/book dynam remaind
importantli also boost ebitda guidanc million
million impli deterior margin expect like continu
increment hire support growth boost ep guidanc
midpoint beat also reflect lower tax rate balanc
year
charl martineau pm univers toronto figur backlog convers remain well industri averag
backlog convers compar due
vs prior
note industri averag adjust vari definit recognit backlog less aggress depend compani
custom mix updat note follow metric report basi
small biopharmaceut compani repres revenu ytd vs
underscor greater exposur faster grow albeit volatil custom
exposur smaller sometim pre-revenu sponsor compani help contribut
rel divers custom base top five custom repres
revenu vs medp custom base concentr rel stabl
overal previou quarter disclosur top contribut revenu
